Complete References

Chapman

[1](Chapman - figure 2) Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev. 2006 Sep;58(3):342-74.

[2](Chapman - figure 2) Kontush A, Chapman MJ. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr Opin Lipidol (2010); 21: 312-318.

[3](Chapman - figure 3) Gordon SM, Hofmann S, Askew DS, Davidson WS. High density lipoprotein: it's not just about lipid transport anymore. Trends Endocrinol. Metab., 22, 9-15 (2011)

[4](Chapman - figure 4) Gwynne J, Brewer HB, Edelhoch H. The molecular behavior of apoa-i in human high density lipoproteins. J Biol Chem 1976; 260():2269-2274.

[5](Chapman - figure 4) Brewer HB, Fairwell T, LaRue A, et al. The amino acid sequence of human Apoa-I, an apolipoprotein isolated from high density lipoproteins. Biochem Biophys Res Comm 1978;80(3):623-630.

[6](Chapman - figure 4) Segrest JP, Jackson RL, Morisette JD, Gotto AM Jr. A molecular theory of lipid-protein interactions in the plasma lipoproteins, FEBS Lett. 1974; 38: 247–258.

[7](Chapman - figure 7) From the lab of W. Sean Davidson: Gangani RA, Silva D, Huang R, et al. Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizes. PNAS 2008;105(34):12176-81.

[8](Chapman - figure 8) Huang R, Gangani RA, Silva D, et al. Apolipoprotein A-I structural organization in high- density lipoproteins isolated from human plasma. Nature Stuct Mol Biol 2011; 18: 416- 422.

[9](Chapman - figure 10) For example: Heinecke J. The role of myeloperoxidase in HDL oxidation and atherogenesis. Curr Athero Rep 2007; 9(4); 249-251.

[10](Chapman - figure 12) Wiesner P, Leidl K, Boettcher A, et al. Lipid profiling of FPLC-separated lipoprotein fractions byelectrospray ionization tandem mass spectrometry. J Lipid Res 2009;50:574- 585.

[11](Chapman - figure 19) Chapman MJ, Ginsberg HN, Amarenco P et al; European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011; 32: 1345-61

Barter

[12](Barter - figure 2) The Emerging Risk Factors Collaboration. Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality. JAMA. 2009;302(4):412- 423.

[13](Barter - figure 3) LaRosa JC, Grundy SM, Waters DD, et al. Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. N Engl J Med 2005;352.

[14](Barter - figure 3) Barter P, Gotto AM, LaRosa JC, et al. HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events. N Engl J Med 2007; 357:1301-1310

[15](Barter - figure 10) Thompson A, DeAngelantonio E, Sarwar N, et al. Association of Cholesteryl Ester Transfer Protein Genotypes With CETP Mass and Activity, Lipid Levels, and Coronary Risk. JAMA 2008; 299: 2777-2788.

[16](Barter - figure 11) Barter PJ, Caulfield M, Eriksson M, et al. Effects of Torcetrapib in Patients at High Risk for Coronary Events. N Engl J Med 2007;357:2109-22.

[17](Barter - figure 15) Matsuura F, Want N, Wengen Chen, et al. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. J Clin Invest 2006: 116(5): 1435-1441.

[18](Barter - figure 15) Yvan-Charvet L, Matsuura F, Wang N, et al. Inhibition of Cholesteryl Ester Transfer Protein by Torcetrapib Modestly Increases Macrophage Cholesterol Efflux to HDL. Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27:1132

[19](Barter - figure 16) Yvan-Charvet L, Kling J, Pagler T, et al. Cholesterol Efflux Potential and Antiinflammatory Properties of High-Density Lipoprotein After Treatment With Niacin or Anacetrapib. Arteriosclerosis, Thrombosis, and Vascular Biology. 2010;30:1430.

[20](Barter - figure 17) Nicholls SJ, Tuzcu M, Brennan DM. Cholesteryl Ester Transfer Protein Inhibition, High- Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis. Circulation. 2008;118:2506-2514.

[21](Barter - figure 20, figure 21) Forrest MJ, Bloomfield D, Briscoe RJ, Brown PN, Cumiskey AM, Ehrhart J, Hershey JC, Keller WJ, Ma X, McPherson HE, Messina E, Peterson LB, Sharif-Rodriguez W, Siegl PK, Sinclair PJ, Sparrow CP, Stevenson AS, Sun SY, Tsai C, Vargas H, Walker M III, West SH, White V, Woltmann RF. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol. 2008; 154: 1465–1473.

[22](Barter - figure 20, figure 21) Hu X, Dietz JD, Xia C, et al. Torcetrapib Induces Aldosterone and Cortisol Production by an Intracellular Calcium-Mediated Mechanism Independently of Cholesteryl Ester Transfer Protein Inhibition. Endocrinology 2009:150:2211-2219.

[23](Barter - figure 21) Capponi AM, Clerc RG, Campos L. No increase in the in vitro production of aldosterone or the expression of CYP11B2 with the CETP modulator dalcetrapib (RO4607381/JTT- 705), in contrast with torcetrapib. Circulation. 2008;118(Suppl 2):S452

[24](Barter - figure 25) Cannon CP et al. Safety of anacetrapib in patients with or at high risk of coronary heart disease. NEJM 2010; 363: 2406–13.

[25](Barter - figure 26) Barter PJ, Caulfield M, Eriksson M, et al. Effects of Torcetrapib in Patients at High Risk for Coronary Events. N Engl J Med 2007;357:2109-22.

[26](Barter - figure 26) Cannon CP et al. Safety of anacetrapib in patients with or at high risk of coronary heart disease. NEJM 2010; 363: 2406–13.

Schaefer

[27](Schaefer - figure 6) Asztalos BF, de la Llera-Moya M, Dallal GE, et al. Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux. J Lipid Res 2005;46:2246-2253.

[28](Schaefer - figure 9) Asztalos BF, Adrienne Cupples L, Demissie S, et al. Prevalence in Male Participants of the Framingham Offspring Study High-Density Lipoprotein Subpopulation Profile and Coronary Heart Disease. Arterioscler Thromb Vasc Biol. 2004;24:2181-2187.

[29](Schaefer - figure 14) HATS: Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345:1583-92.

[30](Schaefer - figure 14) Particle size analysis: Asztalos BF, Batista M, Horvath KV, Cox CE, Dallal GE, Morse JS, Brown GB, Schaefer EJ. Change in alpha 1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol 2003;23:847-852.

[31](Schaefer - figure 17) Brown BG, Stukovsky KH, Zhao XQ: Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. Curr Opin Lipidol 2006;17:631-636.

[32](Schaefer - figure 19) Qiu X, Mistry A, Mark J Ammirati MJ, et al. Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat Struct Mol Biol. 2007;14:106-113.

[33](Schaefer - figure 19) Clark RW, Ruggeri RB, Cunningham D, Bamberger MJ. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res 2006;47:537-552.

[34](Schaefer - figure 21) Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003;290(17):2292-2300.

[35](Schaefer - figure 21) Tardif J-C, Gregoire J, L’Allier PL, et al. Effects of Reconstituted High-Density Lipoprotein Infusions on Coronary Atherosclerosis. JAMA. 2007;297(15):1675-1682.

Rosenson

[36](Rosenson - figure 2) Glomset JA, Wright JL. Some properties of a cholesterol esterifying enzyme in human plasma, Biochim. Biophys. Acta 89 (1964), pp. 266–276.

[37](Rosenson - figure 2) Glomset JA, Norum KR. The metabolic role of lecithin: cholesterol acyltransferase: perspectives form pathology. Adv Lipid Res 1973;11:1-65.

[38](Rosenson - figure 2) The Emerging Risk Factors Collaboration. Separate and combined associations of body- mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. The Lancet 2011;377(9771):1085-1095.

[39](Rosenson - figure 2) Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. The Lancet 2010;376(9753):1670-1681.

[40](Rosenson - figure 2) Keech AC, Rosenson RS, Barnes E, Sacks F, Simes J, Neil HA, and cholesterol treatment trialists’ collaborators. Low HDL-C carries residual risk even at target LDL- C among patients in the cholesterol treatment trialists’ collaboration studies. Circulation 2010;122:A19010.

[41](Rosenson - figure 6) Otvos, JD, Cromwell, W, Shalaurova, I, Schaefer, EJ. LDL particles, but not ldl cholesterol, are highly elevated in the metabolic syndrome: results from the Framingham Offspring Study. Circulation 2003; 108 (Suppl IV):740.

[42](Rosenson - figure 6) Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol. 2000; 86: 943–949

[43](Rosenson - figure 6) Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk. Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31(4):811-822.

[44](Rosenson - figure 6) Contois JH, McConnell JP, Sethi AA, Csako G, Devaraj S, Hoefner DM, Warnick GR ; AACC Lipoportiens and Vascular Diseases Division Working Group on Best Practices. Clin Chem. 2009; 55:407-419

[45](Rosenson - figure 8) van der Steeg WA, Holme I, Boekholdt SM, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk. J Am Coll Cardiol, 2008; 51:634-642.

[46](Rosenson - figure 9) Mackey RH, Greenland P, Goff DC, et al. The relationship of HDL cholesterol and HDL particles to carotid atherosclerosis and incident cardiovascular events: The Multi- Ethnic Study of Atherosclerosis. Abstracts from the American Heart Association Joint Conference: Nutrition, Physical Activity and Metabolism and Metabolism and CVD Epidemiology and Prevention 2011 Scientific Sessions. 2011;331. Abstract P410

[47](Rosenson - figure 11) Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and vardiovascular events. N Engl J Med 2007; 357:1301-1310.

[48](Rosenson - figure 11) Mackey RH, Greenland P, Goff DC, et al. The relationship of HDL cholesterol and HDL particles to carotid atherosclerosis and incident cardiovascular events: The Multi- Ethnic Study of Atherosclerosis. Abstracts from the American Heart Association Joint Conference: Nutrition, Physical Activity and Metabolism and Metabolism and CVD Epidemiology and Prevention 2011 Scientific Sessions. 2011;331. Abstract P410.

[49](Rosenson - figure 12) Mackey RH, Greenland P, Goff DC, et al. The relationship of HDL cholesterol and HDL particles to carotid atherosclerosis and incident cardiovascular events: The Multi- Ethnic Study of Atherosclerosis. Abstracts from the American Heart Association Joint Conference: Nutrition, Physical Activity and Metabolism and Metabolism and CVD Epidemiology and Prevention 2011 Scientific Sessions. 2011;331. Abstract P410.

[50](Rosenson - figure 14) Glomset JA, Wright JL. Some properties of a cholesterol esterifying enzyme in human plasma, Biochim. Biophys. Acta 89 (1964), pp. 266–276.

[51](Rosenson - figure 15) Khera AV, Cuchel M, de la Llera-Moya M, el. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011 Jan 13;364(2):127-35.

[52](Rosenson - figure 16) Rosenson RS, Brewer HB, Chapman MJ, et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 2011;57:392-410.